Base de dados : MEDLINE
Pesquisa : D08.811.277.352.650.035 [Categoria DeCS]
Referências encontradas : 48989 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 4899 ir para página                         

  1 / 48989 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29268128
[Au] Autor:Jafari B; Ospanov M; Ejaz SA; Yelibayeva N; Khan SU; Amjad ST; Safarov S; Abilov ZA; Turmukhanova MZ; Kalugin SN; Ehlers P; Lecka J; Sévigny J; Iqbal J; Langer P
[Ad] Endereço:Institut für Chemie, Universität Rostock, Albert-Einstein-Str. 3a, 18059 Rostock, Germany.
[Ti] Título:2-Substituted 7-trifluoromethyl-thiadiazolopyrimidones as alkaline phosphatase inhibitors. Synthesis, structure activity relationship and molecular docking study.
[So] Source:Eur J Med Chem;144:116-127, 2018 Jan 20.
[Is] ISSN:1768-3254
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:Alkaline Phosphatases (APs) play a key role in maintaining a ratio of phosphate to inorganic pyrophosphate (P /PP ) and thus regulate extracellular matrix calcification during bone formation and growth. Among different isozymes of AP, aberrant increase in the level of tissue non-specific alkaline phosphatase (TNAP) is strongly associated with vascular calcification and end-stage renal diseases. In this context, we synthesized a novel series of fluorinated pyrimidone derivatives, i.e., 2-bromo-7-trifluoromethyl-5-oxo-5H-1,3,4-thiadiazolepyrimidones. The bromine functionality was further used for derivatisation by nucleophilic aromatic substitution using amines as nucleophiles as well as by Palladium catalysed Suzuki-Miyaura reactions. The synthesized derivatives were found potent but non-selective inhibitors of both isozymes of AP. Arylated thiadiazolopyrimidones exhibited stronger inhibitory activities than 2-amino-thiadiazolopyrimidones. The binding modes and possible interactions of the most active inhibitor within the active site of the enzyme were observed by molecular docking studies.
[Mh] Termos MeSH primário: Fosfatase Alcalina/antagonistas & inibidores
Inibidores Enzimáticos/química
Inibidores Enzimáticos/farmacologia
Pirimidinonas/química
Pirimidinonas/farmacologia
Tiadiazóis/química
Tiadiazóis/farmacologia
[Mh] Termos MeSH secundário: Fosfatase Alcalina/metabolismo
Inibidores Enzimáticos/síntese química
Halogenação
Seres Humanos
Simulação de Acoplamento Molecular
Pirimidinonas/síntese química
Relação Estrutura-Atividade
Tiadiazóis/síntese química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Enzyme Inhibitors); 0 (Pyrimidinones); 0 (Thiadiazoles); EC 3.1.3.1 (Alkaline Phosphatase)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171222
[St] Status:MEDLINE


  2 / 48989 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:29267673
[Au] Autor:Yan Y; Qi S; Gong SQ; Shang G; Zhao Y
[Ad] Endereço:Tongji University, Shanghai Engineering Research Center of Tooth Restoration and Regeneration, Department of Pediatric Dentistry, Shanghai, China.
[Ti] Título:Effect of CRABP2 on the proliferation and odontoblastic differentiation of hDPSCs.
[So] Source:Braz Oral Res;31:e112, 2017 Dec 18.
[Is] ISSN:1807-3107
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:Cellular retinoic acid-binding protein 2 (CRABP2) has been detected in several organs during embryonic development. Recent studies have demonstrated that CRABP2 plays important roles in the retinoic acid, ß-catenin and Notch signaling pathways, as well as in the interaction between epithelial and mesenchymal cells, which are important for human dental pulp stem cells (hDPSCs) and tooth development. In the present study, the expression of CRABP2 during mouse molar development and the role of CRABP2 in hDPSC odontoblastic differentiation were evaluated. CRABP2 was gradually decreased during the development of the first maxillary molar, which exhibited the same trend as the expression of CRABP2 during the odontoblastic induction of hDPSCs. CRABP2 knockdown inhibited the proliferative ability of hDPSCs, while it enhanced odontoblastic differentiation via promoting mineralization nodule formation and upregulating the activity of alkaline phosphatase and the expression of mineralization-related genes. The present study uncovered a novel function of CRABP2 in hDPSCs. Our data suggest that CRABP2 may act as a regulator during the proliferation and differentiation of hDPSCs.
[Mh] Termos MeSH primário: Diferenciação Celular/fisiologia
Proliferação Celular/fisiologia
Polpa Dentária/citologia
Odontoblastos/fisiologia
Receptores do Ácido Retinoico/fisiologia
Células-Tronco/fisiologia
[Mh] Termos MeSH secundário: Fosfatase Alcalina
Análise de Variância
Animais
Antraquinonas
Western Blotting
Comunicação Celular
Células Cultivadas
Corantes
Regulação para Baixo/fisiologia
Feminino
Seres Humanos
Imuno-Histoquímica
Masculino
Camundongos Endogâmicos C57BL
Receptores do Ácido Retinoico/análise
Valores de Referência
Reação em Cadeia da Polimerase Via Transcriptase Reversa
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anthraquinones); 0 (Coloring Agents); 0 (Receptors, Retinoic Acid); 0 (retinoic acid binding protein II, cellular); 60MEW57T9G (alizarin); EC 3.1.3.1 (Alkaline Phosphatase)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:D; IM
[Da] Data de entrada para processamento:171222
[St] Status:MEDLINE


  3 / 48989 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28453701
[Au] Autor:Sartor O; Coleman RE; Nilsson S; Heinrich D; Helle SI; O'Sullivan JM; Vogelzang NJ; Bruland Ø; Kobina S; Wilhelm S; Xu L; Shan M; Kattan MW; Parker C
[Ad] Endereço:Departments of Medicine and Urology, Tulane Cancer Center, New Orleans, USA.
[Ti] Título:An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223.
[So] Source:Ann Oncol;28(5):1090-1097, 2017 05 01.
[Is] ISSN:1569-8041
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Background: Baseline clinical variables are prognostic for overall survival (OS) in patients with castration-resistant prostate cancer (CRPC). Their prognostic and predictive value with agents targeting bone metastases, such as radium-223, is not established. Patients and methods: The radium-223 ALSYMPCA trial enrolled patients with CRPC and symptomatic bone metastases. Prognostic potential of baseline variables was assessed using Cox models. Percentage changes in biomarker levels from baseline were evaluated during the trial period; changes from baseline to week 12 were evaluated for association with OS and surrogacy. Results: Eastern Cooperative Oncology Group performance status, total alkaline phosphatase (tALP), lactate dehydrogenase (LDH), and prostate-specific antigen (PSA) at baseline were associated with OS (P ≤ 0.0003) in the intent-to-treat population (radium-223, N = 614; placebo, N = 307). tALP declined from baseline within 4 weeks after beginning radium-223, by week 12 declining in 87% of radium-223 and 23% of placebo patients (P < 0.001). LDH declined in 51% and 34% (P = 0.003), whereas PSA declined in 27% and 14% (P = 0.160). Mean tALP change from baseline was 32.2% decrease with radium-223 and 37.2% increase with placebo. Radium-223 patients with tALP decline from baseline to week 12 (confirmed ≥3 weeks from week 12) had 55% lower risk of death (hazard ratio = 0.45; 95% CI 0.34-0.61) versus those with no confirmed tALP decline. Proportional treatment effect (PTE) values for tALP, LDH, and PSA changes from baseline at week 12 as OS surrogate markers were 0.34 (95% CI: 0-0.746), 0.07 (95% CI: 0-0.211), and 0 (95% CI: 0-0.082), respectively. Conclusions: Significant tALP declines (versus placebo) occurred as early as 4 weeks after beginning radium-223 therapy. tALP or LDH declines at 12 weeks correlated with longer OS, but did not meet statistical surrogacy requirements. Dynamic changes in tALP and LDH during radium-223 treatments may be useful to monitor, but do not serve as surrogates for survival.
[Mh] Termos MeSH primário: Neoplasias de Próstata Resistentes à Castração/radioterapia
Compostos Radiofarmacêuticos/uso terapêutico
Rádio (Elemento)/uso terapêutico
[Mh] Termos MeSH secundário: Fosfatase Alcalina/metabolismo
Biomarcadores Tumorais/metabolismo
Seres Humanos
Calicreínas/metabolismo
Estimativa de Kaplan-Meier
L-Lactato Desidrogenase/metabolismo
Masculino
Análise Multivariada
Prognóstico
Modelos de Riscos Proporcionais
Antígeno Prostático Específico/metabolismo
Neoplasias de Próstata Resistentes à Castração/enzimologia
Neoplasias de Próstata Resistentes à Castração/mortalidade
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Radiopharmaceuticals); 0 (Radium-223); EC 1.1.1.27 (L-Lactate Dehydrogenase); EC 3.1.3.1 (Alkaline Phosphatase); EC 3.4.21.- (Kallikreins); EC 3.4.21.- (kallikrein-related peptidase 3, human); EC 3.4.21.77 (Prostate-Specific Antigen); W90AYD6R3Q (Radium)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1093/annonc/mdx044


  4 / 48989 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27778443
[Au] Autor:Krawczyk M; Liebe R; Wasilewicz M; Wunsch E; Raszeja-Wyszomirska J; Milkiewicz P
[Ad] Endereço:Laboratory of Metabolic Liver Diseases, Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.
[Ti] Título:Plasmapheresis exerts a long-lasting antipruritic effect in severe cholestatic itch.
[So] Source:Liver Int;37(5):743-747, 2017 May.
[Is] ISSN:1478-3231
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND & AIMS: The amelioration of refractory cholestatic pruritus after plasmapheresis has been reported in single patients. Here, we analyse the efficacy of plasmapheresis in a cohort of patients with primary biliary cholangitis (PBC). METHODS: Seventeen consecutive patients with PBC (age range 39-85 years, 16 females, 9 with cirrhosis) and refractory pruritus underwent 129 plasmapheresis procedures during 40 admissions. Pruritus was quantified by the 10-point numeric rating scale (NRS) before and after plasmapheresis, as well as ~30 and ~90 days later. RESULTS: The mean pruritus before plasmapheresis did not differ between patients with and without cirrhosis (P>.05). Cirrhotics presented, however, with significantly higher serum alanine aminotransferase (ALT), aspartate transaminase (AST), gamma-glutamyl transpeptidase (GGT), alkaline phosphatase (ALP) and bilirubin before plasmapheresis. Plasmapheresis decreased itching to NRS≤5 in all but five admissions: Mean pruritus decreased from 8.3±1.4 to 3.1±2.2 (P<.0001) in the entire cohort. It also led to a significant decrease in serum ALT, ALP, AST, GGT (all P<.001) and bilirubin (P=.002). Antipruritic effect persisted throughout the 90-days follow-up (P<.0001). The amelioration of pruritus was not affected by the presence of cirrhosis. CONCLUSIONS: Plasmapheresis is a promising method for reducing intractable itch in a significant proportion of PBC patients regardless of liver fibrosis. Long-lasting improvement of symptoms requires repeated procedures.
[Mh] Termos MeSH primário: Colestase/complicações
Cirrose Hepática Biliar/complicações
Plasmaferese
Prurido/terapia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Fosfatase Alcalina/sangue
Aspartato Aminotransferases/sangue
Bilirrubina/sangue
Feminino
Seres Humanos
Fígado/patologia
Masculino
Meia-Idade
Polônia
Prurido/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
EC 2.6.1.1 (Aspartate Aminotransferases); EC 3.1.3.1 (Alkaline Phosphatase); RFM9X3LJ49 (Bilirubin)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180307
[Lr] Data última revisão:
180307
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE
[do] DOI:10.1111/liv.13281


  5 / 48989 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29180865
[Au] Autor:Zeng D; Zhang X; Wang X; Cao L; Zheng A; Du J; Li Y; Huang Q; Jiang X
[Ad] Endereço:Department of Prosthodontics, School of Medicine, Ninth People's Hospital affiliated to Shanghai Jiao Tong University, Shanghai, People's Republic of China.
[Ti] Título:Fabrication of large-pore mesoporous Ca-Si-based bioceramics for bone regeneration.
[So] Source:Int J Nanomedicine;12:8277-8287, 2017.
[Is] ISSN:1178-2013
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:Our previous study revealed that mesoporous Ca-Si-based materials exhibited excellent osteoconduction because dissolved ions could form a layer of hydroxycarbonate apatite on the surface of the materials. However, the biological mechanisms underlying bone regeneration were largely unknown. The main aim of this study was to evaluate the osteogenic ability of large-pore mesoporous Ca-Si-based bioceramics (LPMSCs) by alkaline phosphatase assay, real-time PCR analysis, von Kossa, and alizarin red assay. Compared with large-pore mesoporous silica (LPMS), LPMSCs had a better effect on the osteogenic differentiation of dental pulp cells. LPMSC-2 and LPMSC-3 with higher calcium possessed better osteogenic abilities than LPMSC-1, which may be related to the calcium-sensing receptor pathway. Furthermore, the loading capacity for recombinant human platelet-derived growth factor-BB was satisfactory in LPMSCs. In vivo, the areas of new bone formation in the calvarial defect repair were increased in the LPMSC-2 and LPMSC-3 groups compared with the LPMSC-1 and LPMS groups. We concluded that LPMSC-2 and LPMSC-3 possessed both excellent osteogenic abilities and satisfactory loading capacities, which may be attributed to their moderate Ca/Si molar ratio. Therefore, LPMSCs with moderate Ca/Si molar ratio might be potential alterative grafts for craniomaxillofacial bone regeneration.
[Mh] Termos MeSH primário: Regeneração Óssea/fisiologia
Cálcio/química
Teste de Materiais/métodos
Dióxido de Silício/química
[Mh] Termos MeSH secundário: Fosfatase Alcalina/metabolismo
Animais
Antraquinonas/análise
Antraquinonas/metabolismo
Materiais Biocompatíveis/química
Compostos de Cálcio/química
Diferenciação Celular
Cerâmica/química
Polpa Dentária/citologia
Seres Humanos
Masculino
Naftalenos/farmacologia
Nitratos/química
Osteogênese/efeitos dos fármacos
Fator de Crescimento Derivado de Plaquetas/genética
Fator de Crescimento Derivado de Plaquetas/metabolismo
Porosidade
Ratos Sprague-Dawley
Reação em Cadeia da Polimerase em Tempo Real
Crânio/lesões
Crânio/fisiologia
Tecidos Suporte
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anthraquinones); 0 (Biocompatible Materials); 0 (Calcium Compounds); 0 (N-(2-hydroxy-3-(2-cyano-3-chlorophenoxy)propyl)-1,1-dimethyl-2-(2-nephthyl)ethylamine); 0 (Naphthalenes); 0 (Nitrates); 0 (Platelet-Derived Growth Factor); 3F3AT0Q12H (Alizarin Red S); 7631-86-9 (Silicon Dioxide); EC 3.1.3.1 (Alkaline Phosphatase); NF52F38N1N (calcium nitrate); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171129
[St] Status:MEDLINE
[do] DOI:10.2147/IJN.S144528


  6 / 48989 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29465590
[Au] Autor:Nishimura T; Arima K; Abe Y; Kanagae M; Mizukami S; Okabe T; Tomita Y; Goto H; Horiguchi I; Aoyagi K
[Ad] Endereço:Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Sakamoto.
[Ti] Título:Relationship between bone turnover markers and the heel stiffness index measured by quantitative ultrasound in middle-aged and elderly Japanese men.
[So] Source:Medicine (Baltimore);97(8):e9962, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The aim of the present study was to investigate the age-related patterns and the relationships between serum levels of tartrate-resistant acid phosphatase-5b (TRACP-5b) or bone-specific alkaline phosphatase (BAP), and the heel stiffness index measured by quantitative ultrasound (QUS) in 429 Japanese men, with special emphasis on 2 age groups (40-59 years and 60 years or over). The heel stiffness index (bone mass) was measured by QUS. Serum samples were collected, and TRACP-5b and BAP levels were measured. The stiffness index was significantly decreased with age. Log (TRACP-5b) was significantly increased with age, but Log (BAP) was stable. Generalized linear models showed that higher levels of Log (TRACP-5b) and Log (BAP) were correlated with a lower stiffness index after adjusting for covariates in men aged 60 years or over, but not in men aged 40 to 59 years. In conclusion, higher rates of bone turnover markers were associated with a lower stiffness index only in elderly men. These results may indicate a different mechanism of low bone mass among different age groups of men.
[Mh] Termos MeSH primário: Fosfatase Alcalina/sangue
Indicadores Básicos de Saúde
Calcanhar/diagnóstico por imagem
Fosfatase Ácida Resistente a Tartarato/sangue
[Mh] Termos MeSH secundário: Adulto
Fatores Etários
Idoso
Idoso de 80 Anos ou mais
Biomarcadores/sangue
Densidade Óssea
Remodelação Óssea/fisiologia
Testes Diagnósticos de Rotina
Calcanhar/fisiopatologia
Seres Humanos
Japão
Modelos Lineares
Masculino
Meia-Idade
Ultrassonografia/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); EC 3.1.3.1 (Alkaline Phosphatase); EC 3.1.3.2 (Tartrate-Resistant Acid Phosphatase)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180222
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009962


  7 / 48989 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29254304
[Au] Autor:Li JK; Wang C; Gong HD; Li HZ
[Ad] Endereço:Department of Neurosurgery, Affiliated HongQi Hospital of Mu Dan Jiang Medical University, Mudanjiang City, China.
[Ti] Título:Coagulation in hindbrain membrane meningioma patients treated with different injections using acute hypervolemic hemodilution.
[So] Source:J Biol Regul Homeost Agents;31(4):991-996, 2017 Oct-Dec.
[Is] ISSN:0393-974X
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:The aim of this study was to analyze the changes in coagulation in meningioma patients treated with different injections using the method of acute hypervolemic hemodilution (AHH). One hundred fifty hindbrain membrane meningioma patients were randomly divided into 5 groups, 30 per group. The first group were injected 40ml/time with Danhong after anesthesia induction; the second group were injected with 40ml~60ml/time Kangai and combined with interventional chemotherapy and embolization procedure; the third group of AHH were injected with polygeline 15ml/kg; the fourth group were injected with hydroxyethyl starch (130/0.4) sodium chloride in doses of 15ml/kg; the control group underwent basic treatment for lowering blood pressure and lowering blood fat. The changes of coagulation index were recorded before and after surgery and before and after the injection of different medications. Compared to the control group, for the first group of AHH, after being treated for 10 days and 30 days, the concentrations of bone specific alkaline phosphatase (BALP), bone Gla protein (BGP) and pro-collagen carboxy-terminal propeptide (PICP) were higher than that of the control group, the levels of endotoxin (ET) and C-reactive protein (CRP) were decreased compared to the control group (p less than 0.05); for the second group of AHH, after being treated for 10 days, the index of prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), fibrinogen (Fg) were not significantly changed, but the related level of vascular endothelial growth factor (VEGF) significantly decreased (p less than 0.05). Comparing the coagulation function index after surgery in the third and fourth groups, there were no significant changes in mean arterial pressure (MAP) level, heart rate (HR) value presented a low decrease, central venous pressure (CVP) level increased and the level of interleukin IL-6 showed a steady state after increasing. Analyzing the levels of interleukin IL-8 and tumor necrosis factor-α (TNF-α) after surgery, it was seen that in the third group they increased and in the fourth group they decreased (p less than 0.05). Danhong injection improved the coagulation function and microcirculation of patients, Kangai injection and interventional chemotherapy and embolization restrained the appearance of tumor angiogenesis, AHH operation with polygeline injection and hydroxyethyl starch (130/0.4) sodium chloride kept blood flow in normal parameters.
[Mh] Termos MeSH primário: Coagulação Sanguínea/efeitos dos fármacos
Cardiotônicos/uso terapêutico
Medicamentos de Ervas Chinesas/uso terapêutico
Hemodiluição/métodos
Neoplasias Meníngeas/tratamento farmacológico
Meningioma/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Fosfatase Alcalina/genética
Fosfatase Alcalina/metabolismo
Pressão Arterial/efeitos dos fármacos
Pressão Arterial/fisiologia
Biomarcadores/metabolismo
Viscosidade Sanguínea/efeitos dos fármacos
Proteína C-Reativa/genética
Proteína C-Reativa/metabolismo
Embolização Terapêutica/métodos
Endotoxinas/metabolismo
Feminino
Fibrinogênio/genética
Fibrinogênio/metabolismo
Expressão Gênica
Frequência Cardíaca/efeitos dos fármacos
Frequência Cardíaca/fisiologia
Seres Humanos
Derivados de Hidroxietil Amido/administração & dosagem
Masculino
Neoplasias Meníngeas/sangue
Neoplasias Meníngeas/patologia
Neoplasias Meníngeas/cirurgia
Meningioma/sangue
Meningioma/patologia
Meningioma/cirurgia
Meia-Idade
Osteocalcina/genética
Osteocalcina/metabolismo
Fragmentos de Peptídeos/genética
Fragmentos de Peptídeos/metabolismo
Substitutos do Plasma/administração & dosagem
Poligelina/administração & dosagem
Pró-Colágeno/genética
Pró-Colágeno/metabolismo
Rombencéfalo/efeitos dos fármacos
Rombencéfalo/metabolismo
Rombencéfalo/patologia
Rombencéfalo/cirurgia
Fator A de Crescimento do Endotélio Vascular/genética
Fator A de Crescimento do Endotélio Vascular/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Cardiotonic Agents); 0 (Drugs, Chinese Herbal); 0 (Endotoxins); 0 (Hydroxyethyl Starch Derivatives); 0 (Peptide Fragments); 0 (Plasma Substitutes); 0 (Procollagen); 0 (VEGFA protein, human); 0 (Vascular Endothelial Growth Factor A); 0 (danhong); 0 (procollagen type I carboxy terminal peptide); 104982-03-8 (Osteocalcin); 9001-32-5 (Fibrinogen); 9007-41-4 (C-Reactive Protein); 9015-56-9 (Polygeline); EC 3.1.3.1 (Alkaline Phosphatase)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171220
[St] Status:MEDLINE


  8 / 48989 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29251476
[Au] Autor:Singh G; Sharma P; Sharma S
[Ti] Título:Role of growth media on the phytopromotional potential of symbiotic fungus Piriformospoira indica.
[So] Source:J Environ Biol;37(5):889-94, 2016 09.
[Is] ISSN:0254-8704
[Cp] País de publicação:India
[La] Idioma:eng
[Ab] Resumo:Piriformospora indica biomass generated in different growth media Rose Bengal medium, Kaefer's Medium, Enriched Soil Medium, Malt extract Medium and Czapek Dox was quantified and? their bioinoculum potential was compared using? moong bean (Vigna radiata) as? test plant. Plant chlorophyll content in response to inoculations was lowest in Rose Bengal medium (2.772mg plant-1) and highest due to inoculum produced on Enriched soil Medium (3.694 mg plant-1). The highest nitrogen content (19.260 mg plant-1) was recorded by inoculum produced on Kaefer's Medium followed by Enriched Soil Medium (19.123 mg plant-1), ME (18.19 mg plant-1) and CD medium (17.71 mg plant-1). The highest plant phosphorus uptake was registered in Enriched Soil Medium (17.153 mg plant-1) followed by Kaefer's Medium (17.023 mg plant-1). Maximum dry weight of plants was observed by inoculation with fungus cultured in Kaefer's Medium (3.416 g pot-1) and Enriched Soil Medium (3.349 g pot-1). Thus, growth medium used for the culture of fungus can influence its bioefficacy as plant growth promoting agent and Piriformospora indica can be grown on cost effective and simple mass multiplication medium which could augment its usage for commercial purposes.
[Mh] Termos MeSH primário: Basidiomycota/fisiologia
Endófitos
Fabaceae/crescimento & desenvolvimento
Fabaceae/microbiologia
[Mh] Termos MeSH secundário: Fosfatase Ácida/metabolismo
Fosfatase Alcalina/metabolismo
Regulação Enzimológica da Expressão Gênica/fisiologia
Regulação da Expressão Gênica de Plantas/fisiologia
Raízes de Plantas/microbiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
EC 3.1.3.1 (Alkaline Phosphatase); EC 3.1.3.2 (Acid Phosphatase)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171219
[St] Status:MEDLINE


  9 / 48989 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29244613
[Au] Autor:Susini V; Rossi VL; Sanesi A; Drazek L
[Ad] Endereço:a Department of Chemistry Ugo Schiff, University of Florence , Florence , Italy.
[Ti] Título:Kinetics study on recombinant alkaline phosphatase and correlation with the generated fluorescent signal.
[So] Source:J Immunoassay Immunochem;39(1):108-118, 2018.
[Is] ISSN:1532-4230
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Alkaline phosphatase (AP) (EC 3.1.3.1) is one of the most commonly used enzymes in immunoassays. In VIDAS® assays (bioMérieux, Marcy l'Etoile, France), AP catalyzes the hydrolysis of 4-methylumbelliferyl phosphate (4-MUP) in 4-methylumbelliferone (4-MU) producing a fluorescent signal. This work introduces an original method of characterization of the kinetic parameters K , V and K of AP embedded in VIDAS® assays. Assessment of such constants allows us to predict the fluorescent signal generated for given amounts of enzyme and its associated substrate; in the particular case of VIDAS®, it has been estimated that 0.06 nmol/L of AP produces 3144 Relative Fluorescent Values (RFV). ABBREVIATIONS: 4-MUP, 4-Methylumbelliferyl phosphate; 4-MU, 4-Methylumbelliferone; RFV, Relative Fluorescent Values; RFU, Relative Fluorescent Units; QDs, Quantum Dots; LoD, Limit of Detection.
[Mh] Termos MeSH primário: Fosfatase Alcalina/metabolismo
Fluorescência
[Mh] Termos MeSH secundário: Fosfatase Alcalina/química
Biocatálise
Ensaio de Imunoadsorção Enzimática
Hidrólise
Himecromona/análogos & derivados
Himecromona/química
Himecromona/metabolismo
Cinética
Proteínas Recombinantes/química
Proteínas Recombinantes/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Recombinant Proteins); 3368-04-5 (4-methylumbelliferyl phosphate); 3T5NG4Q468 (Hymecromone); EC 3.1.3.1 (Alkaline Phosphatase)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171216
[St] Status:MEDLINE
[do] DOI:10.1080/15321819.2017.1408022


  10 / 48989 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28448457
[Au] Autor:Schwetz V; Trummer C; Pandis M; Grübler MR; Verheyen N; Gaksch M; Zittermann A; März W; Aberer F; Lang A; Treiber G; Friedl C; Obermayer-Pietsch B; Pieber TR; Tomaschitz A; Pilz S
[Ad] Endereço:Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz 8036, Austria. verena.schwetz@medunigraz.at.
[Ti] Título:Effects of Vitamin D Supplementation on Bone Turnover Markers: A Randomized Controlled Trial.
[So] Source:Nutrients;9(5), 2017 Apr 27.
[Is] ISSN:2072-6643
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Bone turnover markers (BTMs) are used to evaluate bone health together with bone mineral density and fracture assessment. Vitamin D supplementation is widely used to prevent and treat musculoskeletal diseases but existing data on vitamin D effects on markers of bone resorption and formation are inconsistent. We therefore examined the effects of vitamin D supplementation on bone-specific alkaline phosphatase (bALP), osteocalcin (OC), C-terminal telopeptide (CTX), and procollagen type 1 N-terminal propeptide (P1NP). This is a post-hoc analysis of the Styrian Vitamin D Hypertension Trial, a single-center, double-blind, randomized, placebo-controlled trial (RCT) performed at the Medical University of Graz, Austria (2011-2014). Two hundred individuals with arterial hypertension and 25-hydroxyvitamin D (25[OH]D) levels <75 nmol/L were randomized to 2800 IU of vitamin D daily or placebo for eight weeks. One hundred ninety-seven participants (60.2 ± 11.1 years; 47% women) were included in this analysis. Vitamin D had no significant effect on bALP (mean treatment effect (MTE) 0.013, 95% CI -0.029 to 0.056 µg/L; = 0.533), CTX (MTE 0.024, 95% CI -0.163 to 0.210 ng/mL, = 0.802), OC (MTE 0.020, 95% CI -0.062 to 0.103 ng/mL, = 0.626), or P1NP (MTE -0.021, 95% CI -0.099 to 0.057 ng/mL, = 0.597). Analyzing patients with 25(OH)D levels <50 nmol/L separately ( = 74) left results largely unchanged. In hypertensive patients with low 25(OH)D levels, we observed no significant effect of vitamin D supplementation for eight weeks on BTMs.
[Mh] Termos MeSH primário: Remodelação Óssea/efeitos dos fármacos
Vitamina D/administração & dosagem
Vitamina D/farmacologia
[Mh] Termos MeSH secundário: Idoso
Fosfatase Alcalina/genética
Fosfatase Alcalina/metabolismo
Biomarcadores/sangue
Método Duplo-Cego
Feminino
Regulação da Expressão Gênica/efeitos dos fármacos
Seres Humanos
Masculino
Meia-Idade
Osteocalcina/genética
Osteocalcina/metabolismo
Fragmentos de Peptídeos/genética
Fragmentos de Peptídeos/metabolismo
Pró-Colágeno/genética
Pró-Colágeno/metabolismo
Vitamina D/análogos & derivados
Vitamina D/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Biomarkers); 0 (Peptide Fragments); 0 (Procollagen); 0 (procollagen Type I N-terminal peptide); 104982-03-8 (Osteocalcin); 1406-16-2 (Vitamin D); 64719-49-9 (25-hydroxyvitamin D); EC 3.1.3.1 (Alkaline Phosphatase)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170428
[St] Status:MEDLINE



página 1 de 4899 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde